Approaches to countermeasures against infection by new coronaviruses
May 21, 2020
Japan Pharmaceutical Manufacturers Association
Chairman: Yuzuru Nakayama
I would like to express my deepest condolences to those who have suffered and lost their lives due to the new type of coronavirus infection, both in Japan and overseas, and my deepest sympathy to all those who are fighting the disease.
I would also like to express my heartfelt gratitude to all the medical professionals who are working hard on the front lines of infectious disease countermeasures and treatment.
Japan Pharmaceutical Manufacturers Association (JPMIA) recognizes that the rapid research and development of effective and safe therapeutic drugs and vaccines is an important means toward the end of the global epidemic of novel coronavirus infection, and our member companies are committed and diligent in their efforts to achieve this goal.
Specific directions of efforts include the diversion of existing drugs (drug repositioning), the creation of vaccines, and the creation of new therapeutic agents. All of these efforts require appropriate evaluation of efficacy and safety, and each company is doing its utmost to expedite these efforts. The industry association is committed to promoting collaboration among industry, academia, and government in order to further accelerate these efforts.
We have decided to provide information on these efforts by our member companies through a special website entitled "New Coronavirus Infectious Disease Countermeasures". For details, please visit this website.
- Special site "Measures against new coronavirus infection